In the News

News & Publications

  • Filter by type

October 16, 2023 | Press Release

LONDON – October 16, 2023 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients …

Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole Read More »

June 8, 2023 | Press Release

LONDON, June 08, 2023 — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering …

Pulmocide Announces Expansion of Management Team Read More »

December 6, 2022 | Press Release

Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic …

Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole Read More »

December 21, 2021 | Press Release

Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients …

Pulmocide Receives Investment from the Cystic Fibrosis Foundation Read More »

May 27, 2021 | Press Release

– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and …

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 Read More »

October 26, 2020 | Publications & Presentations

London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening …

Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development Read More »

Scroll to Top